| Literature DB >> 27194004 |
Paolo Poggio1, Laura Cavallotti2, Paola Songia3, Alessandro Di Minno4, Pasquale Ambrosino5, Liborio Mammana2, Alessandro Parolari6, Francesco Alamanni2, Elena Tremoli3, Matteo Nicola Dario Di Minno7.
Abstract
BACKGROUND: Literature studies suggested a lower prevalence of coronary artery disease (CAD) in bicuspid aortic valve (BAV) than in tricuspid aortic valve (TAV) patients. However, this finding has been challenged. We performed a meta-analysis to assess whether aortic valve morphology has a different association with CAD, concomitant coronary artery bypass grafting (CABG), and postoperative mortality. METHODS ANDEntities:
Keywords: aortic valve morphology; bicuspid aortic valve; coronary artery disease
Mesh:
Year: 2016 PMID: 27194004 PMCID: PMC4889190 DOI: 10.1161/JAHA.116.003200
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1PRISMA flow diagram. BAV indicates bicuspid aortic valve; CT, computed tomography.
Demographic and Clinical Data of BAV and TAV
| Author (Year) | Reported Outcomes | Observation Time | Subjects | Age, y | Males | Hypertension | Hyperlipidemia | Diabetes | BMI | Smoking | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdulkareem 2013 | CABG | BAV | 192 | 58 | 71.3 | ||||||
| TAV | 203 | 65 | 62.5 | ||||||||
| Ali 2010 | CABG, mortality | 7 years | BAV | 90 | 63 | 78.9 | 31.1 | 12.2 | 5.6 | ||
| TAV | 125 | 70 | 58.4 | 32.0 | 16.8 | 11.2 | |||||
| Asano 2012 | CABG, mortality | 5 years | BAV | 86 | 46.3 | ||||||
| TAV | 58 | 70 | |||||||||
| Badiu 2010 | CAD, CABG, mortality | 5 years | BAV | 11 | 37 | 100.0 | 45.5 | 9.1 | |||
| TAV | 91 | 48 | 63.7 | 69.2 | 36.3 | 4.4 | |||||
| Boudoulas 2015 | CABG | BAV | 95 | 62 | 71.6 | 70 | 61 | 31 | 53 | ||
| TAV | 175 | 71 | 55.4 | 87 | 60 | 47 | 48 | ||||
| Branchetti 2014 | CAD | BAV | 74 | 55.5 | 64.9 | 31.1 | 27.0 | 5.4 | 43.2 | ||
| TAV | 61 | 64.4 | 70.5 | 42.6 | 42.6 | 13.1 | 19.7 | ||||
| Costopoulos 2014 | Mortality | 1 year | BAV | 21 | 76.7 | 57.1 | 66.7 | 28.6 | 26.6 | ||
| TAV | 447 | 79.8 | 47.4 | 77.2 | 30.2 | 26.1 | |||||
| Davies 1996 | CABG | BAV | 296 | ||||||||
| TAV | 125 | ||||||||||
| Delius 1998 | Mortality | 10 years | BAV | 16 | |||||||
| TAV | 31 | ||||||||||
| Eleid 2013 | CAD, CABG | BAV | 47 | 58 | 76.6 | 68.1 | 48.9 | 8.5 | 23.4 | ||
| TAV | 53 | 66 | 75.5 | 86.8 | 49.1 | 11.3 | 13.2 | ||||
| Etz 2015 | CAD, mortality | Inhospital | BAV | 32 | 46.7 | 71.9 | 46.9 | 15.6 | |||
| TAV | 347 | 61.6 | 63.7 | 72.0 | 9.2 | 10.7 | |||||
| Girdauskas 2014 | Mortality | 10 years | BAV | 153 | 54 | 73.2 | 48.4 | 11.1 | 35.9 | ||
| TAV | 172 | 64 | 47.7 | 57.0 | 15.7 | 40.1 | |||||
| Holubec 2014 | CAD, CABG, mortality | 2 years | BAV | 60 | 45 | 81.7 | 45.0 | ||||
| TAV | 40 | 59 | 67.5 | 75.0 | |||||||
| Hwang 2011 | CAD, mortality | 10 years | BAV | 45 | 59.6 | 60.0 | 44.4 | 2.2 | 6.7 | 26.7 | |
| TAV | 43 | 58.3 | 48.8 | 23.3 | 2.3 | 9.3 | 9.3 | ||||
| Jackson 2014 | CAD | BAV | 292 | 61.1 | 73.6 | 51.0 | 11.3 | ||||
| TAV | 355 | 717 | 69.9 | 74.6 | 14.9 | ||||||
| Kochman 2014 | CAD, mortality | 1 year | BAV | 28 | 77.6 | 46.4 | 60.7 | 39.3 | |||
| TAV | 84 | 79.1 | 47.6 | 65.5 | 34.5 | ||||||
| Kvitting 2013 | CABG | BAV | 63 | 43 | 79.4 | 36.5 | 4.8 | 26 | |||
| TAV | 170 | 36 | 67.6 | 25.9 | 2.4 | 24 | |||||
| Liu 2015 | CAD, mortality | 30 days | BAV | 15 | 75.4 | 60.0 | 33.3 | 23.6 | |||
| TAV | 25 | 75.8 | 68.0 | 56.0 | 12.0 | 21.7 | |||||
| Mosalanezhad 2014 | CABG, mortality | 8 years | BAV | 30 | 42 | 93.3 | |||||
| TAV | 20 | 59 | 75.0 | ||||||||
| Nakamura 2014 | CAD | BAV | 17 | 70 | 76.5 | 58.8 | 35.3 | 17.6 | 35.3 | ||
| TAV | 59 | 77 | 52.5 | 79.7 | 33.9 | 20.3 | 40.7 | ||||
| Philip 2015 | CAD | BAV | 200 | 57 | 23.5 | 21.5 | 10.5 | ||||
| TAV | 200 | 78 | 76.5 | 78.5 | 31.5 | ||||||
| Roberts 2003 | CABG | BAV | 232 | 64.7 | 72.0 | ||||||
| TAV | 267 | 74 | 51.3 | ||||||||
| Roberts 2007a | CABG, mortality | 5 years | BAV | 102 | |||||||
| TAV | 18 | ||||||||||
| Roberts 2007b | CABG, mortality | 4 years | BAV | 187 | |||||||
| TAV | 235 | ||||||||||
| Roberts 2007c | CABG | BAV | 54 | ||||||||
| TAV | 142 | ||||||||||
| Roberts 2007d | CABG, mortality | 13 years | BAV | 180 | |||||||
| TAV | 107 | ||||||||||
| Rylski 2014 | CAD, mortality | Inhospital | BAV | 41 | 55 | 63.4 | 56.1 | 9.8 | |||
| TAV | 588 | 61 | 64.1 | 81.1 | 9.2 | ||||||
| Shim 2011 | CAD | BAV | 50 | 52 | 78.0 | 40.0 | 20.0 | 12.0 | 24.7 | 32.0 | |
| TAV | 50 | 52 | 78.0 | 50.0 | 28.0 | 8.0 | 25.2 | 42.0 | |||
| Stephan 1997 | CABG | BAV | 57 | 67 | 57.9 | ||||||
| TAV | 57 | 73 | 54.4 | ||||||||
| Warner 2013 | CAD | BAV | 10 | 46.5 | 60.0 | 50.0 | 40.0 | 10.0 | 30.1 | 10.0 | |
| TAV | 13 | 46.3 | 76.9 | 38.5 | 46.2 | 23.1 | |||||
| Yuan 2010 | CAD | BAV | 241 | 56.1 | 77.2 | 30.7 | 24.1 | 10.8 | |||
| TAV | 225 | 62.8 | 64.0 | 41.8 | 24.9 |
Data reported as median value. BAV indicates bicuspid aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; TAV, tricuspid aortic valve.
Figure 2Prevalence of coronary artery disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 3Prevalence of coronary artery bypass grafting (CABG) in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 4Post‐operative mortality in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 5Meta‐regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of coronary artery disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 6Meta‐regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of concomitant coronary artery bypass grafting in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Stratification of the Studies: Retrospective and Prospective
| No. of Studies | OR (95% CI) | Heterogeneity | |
|---|---|---|---|
| CAD | |||
| Retrospective studies | 8 | 0.37 (0.18, 0.76; | I2: 84%; |
| Prospective studies | 7 | 0.30 (0.07, 1.32; | I2: 87%; |
| CABG | |||
| Retrospective studies | 15 | 0.45 (0.35, 0.59; | I2: 59%; |
| Prospective studies | 1 | 0.43 (0.02, 7.90; | Not evaluable |
| Mortality | |||
| Retrospective studies | 13 | 0.57 (0.34, 0.94; | I2: 72%; |
| Prospective studies | 3 | 1.08 (0.41, 2.86; | I2: 0%; |
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; OR, odds ratio.